• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
JIN Jing, WANG Xiaojian, ZHOU Wanqi, XUE Nina, YIN Dali, CHEN Xiaoguang. Pharmacological activity of a novel selective S1P1 agonist(prodrug)Syl978[J]. Journal of China Pharmaceutical University, 2014, 45(3): 358-361. DOI: 10.11665/j.issn.1000-5048.20140319
Citation: JIN Jing, WANG Xiaojian, ZHOU Wanqi, XUE Nina, YIN Dali, CHEN Xiaoguang. Pharmacological activity of a novel selective S1P1 agonist(prodrug)Syl978[J]. Journal of China Pharmaceutical University, 2014, 45(3): 358-361. DOI: 10.11665/j.issn.1000-5048.20140319

Pharmacological activity of a novel selective S1P1 agonist(prodrug)Syl978

More Information
  • Syl978 is a synthesized selective S1P1(sphingosine-1-phosphate receptor 1)agonist which is obtained based on the structural modification of fingolimod(FTY720). Biological evaluation in vitro indicated that Syl978-P, the active form of Syl978 demonstrated nanomole S1P1 agonist activity with > 500 selective over S1P3. In SD rats, oral administration of 0. 3, 1 and 3 mg/kg Syl978 significantly decrease the peripheral blood lymphocytes(PBL)in a dose-dependent manner. Oral administration of 10 mg/kg Syl978 had no effect on the heart rate of SD rats. In summary, the above results demonstrated that Syl978 exhibited great selectivity both in vitro and in vivo study, suggesting the potential therapeutic use in the treatment of autoimmune diseases.
  • [1]
    Fung JJ,Alessiani M,Abu-Elmagd K,et al.Adverse effects associated with the use of FK 506[J].Transplant Proc, 1991,23(6):3 105-3 108.
    [2]
    Rosen H,Gonzalez-Cabrera PJ,Sanna MG,et al.Sphingosine 1-phosphate receptor signaling[J].Annu Rev Biochem,2009,78(1):743-768.
    [3]
    Oo ML,Chang SH,Thangada S,et al.Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice[J].J Clin Invest,2011,121(6):2 290-2 300.
    [4]
    Oo ML,Thangada S,Wu MT,et al.Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor[J].J Biol Chem,2007,282(12):9 082-9 089.
    [5]
    Chiba K.FTY720,a new class of immunomodulator,inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors[J].Pharmacol Ther,2005,108(3):308-319.
    [6]
    Brinkmann V, Billich A, Baumruker T, et al. Fingolimod(FTY720):discovery and development of an oral drug to treat multiple sclerosis[J].Nat Rev Drug Discov,2010,9(11):883-897.
    [7]
    Suzuki K,Yan H,Li XK,et al.Prevention of experimentally induced autoimmune type I diabetes in rats by the new immunosuppressive reagent FTY720[J].Transplant Proc,1998,30(4):1 044-1 045.
    [8]
    Tsunemi S,Iwasaki T,Kitano S,et al.Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model[J].Clin Immunol,2010,136(2):197-204.
    [9]
    Wang F,Tan W,Guo D,et al.Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720[J].Eur J Pharmacol,2007,573(1/2/3):230-240.
    [10]
    Billich A,Bornancin F,Devay P,et al.Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases[J].J Biol Chem,2003,278(48):47 408-47 415.
    [11]
    Sanna MG,Liao J,Jo E,et al.Sphingosine 1-phosphate(S1P)receptor subtypes S1P1 and S1P3,respectively,regulate lymphocyte recirculation and heart rate[J].J Biol Chem,2004,279(14):13 839-13 848.
    [12]
    Bergsdorf C,Kropp-Goerkis C,Kaehler I,et al.A one-day,dispense-only IP-One HTRF assay for high-throughput screening of Galphaq protein-coupled receptors:towards cells as reagents[J].Assay Drug Dev Technol,2008,6(1):39-53.
    [13]
    Trinquet E,Bouhelal R,Dietz M.Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-One assay[J].Expert Opin Drug Discov,2011,6(10):981-994.
    [14]
    Foss FW,Jr Snyder AH,Davis MD,et al.Synthesis and biological evaluation of gamma-aminophosphonates as potent,subtype-selective sphingosine 1-phosphate receptor agonists and antagonists[J].Bioorg Med Chem,2007,15(2):663-677.
    [15]
    Hamada M,Nakamura M,Kiuchi M,et al.Removal of sphingosine 1-phosphate receptor-3(S1P(3))agonism is essential,but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P(1)agonists with reduced effect on heart rate[J].J Med Chem,2010,53(8):3 154-3 168.

Catalog

    Article views (1266) PDF downloads (1796) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return